Ardelyx Inc.
07/02/2024 | Press release | Distributed by Public on 07/02/2024 05:05
Material Event Form 8 K
Item 8.01 Other Events.
On July 2, 2024, Ardelyx, Inc. (the Company) announced that, in an effort to preserve patient access to its phosphate absorption inhibitor XPHOZAH® (tenapanor), the Company has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Transitional Drug Add-on Payment Adjustment (TDAPA).